Clinical Trial Update: A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) [Phase 3]

View source ↗

Summary

Phase 3 trial LS-034 evaluating belzutifan (MK-6482) in combination with zanzalintinib for renal cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Belzutifan (belzutifan)
• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: RECRUITING